Question · asked by 1 review
Lower‐dose methylnaltrexone vs higher dose: Serious adverse events
- Population
- people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
- Intervention
- Lower‐dose methylnaltrexone
- Comparison
- higher dose
- Outcome
- Serious adverse events
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Methylnaltrexone lower dose vs higher dose Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction The review found no eligible studies for this question. Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.